“…Specifically in the United Kingdom's National Health Service (NHS), costs per quality-adjusted life-year (QALY) gained are an important criterion in decision-making processes for the adoption of new health technologies. 11 To date, only few economic evaluations on EVH have been published, delivering different conclusions on the cost-effectiveness of EVH, 6,[12][13][14][15] while focusing only on a short-term analytic horizon. To enable more precise and informed decision making on the adoption of EVH as standard of care in the United Kingdom, 10,12 cohort only during the first cycle (transition to a different state after the first cycle).…”